Vitrakvi

Active substance

Larotrectinib

Holder

Bayer

Status

Closed

Indication

Treatment of adult and paediatric patients with locally advanced or metastatic solid tumors with a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion that cannot be treated satisfactorily with the available treatment options

Public documents

Approbation

Information for the patient

Informed consent

Last update

19/04/2021

Last updated on 19/04/2021